Belatacept in De Novo Heart Transplantation

Exclusion Criteria28

• Candidates awaiting multiorgan transplant
• Estimated glomerular filtration rate (eGFR) < 45 ml/min/m2
• Candidates with prior organ transplant
• Candidates actively being treated with immunosuppressive therapies
• Candidates who have a history of treatment with cytolytic therapy (e.g. anti-thymocyte globulin)
• Candidates who are intended to be treated with cytolytic therapy in the post-transplant period as induction therapy
• EBV (IgG) seronegative
• Active or prior infection with human immunodeficiency virus (HIV), Hepatitis C (HCV), Hepatitis B (HBV)
• Untreated latent tuberculosis (TB)
• All potential candidates will be screened prior to enrolment for a history of tuberculosis (chest radiograph and tuberculosis-Interferon Gamma Release Assay (TB-IGRA) or tuberculin skin tests (TST)). Potential candidates with latent TB must be treated prior to study enrolment
• Prior history of active tuberculosis
• Prior history of central nervous system infection
• Known active current viral, fungal, mycobacterial, or other infections excluding driveline infections - potential participants from endemic areas will additionally be screened for histoplasmosis, blastomycosis, coccidioidomycosis, and strongyloidiasis
• Vaccination with a live vaccine within the past 30 days
• Malignancy within the last 5 years
• Any previous treatment with alkylating agents or total lymphoid irradiation
• Sensitized heart transplant candidates with panel-reactive antibodies (PRA) >50% or those receiving desensitization treatment
• Prior treatment with belatacept or abatacept
• History of severe allergic anaphylactic reactions to humanized or murine monoclonal antibodies
• Treatment with a disease modifying anti-rheumatic drug (DMARD) or other biologic agent (monoclonal antibody) within the past year
• Treatment with another investigational drug or other intervention at the time of transplant (excluding device or intervention mechanical support or investigational drug trials where the intervention ends at the time of transplant)
• Potential candidates for whom a calcineurin inhibitor other than tacrolimus (Prograf®) is anticipated after transplant. If during the course of the study, a participant is transitioned to another calcineurin inhibitor due to side effects or inability to achieve stable therapeutic trough levels, they may continue in the study at the discretion of the investigator
• Any potential participant who remains on mechanical circulatory support for > 72 hours post-transplant will be excluded from the study
• The need for ongoing high dose vasopressor support > 72 hours post-transplant
• The need or anticipated need for post-transplant dialysis
• Platelet count <75,000/mm (within 24 hours prior to transplant)
• Absolute neutrophil count (ANC) of less than 2000/mm3 within 24 hours prior to transplant
• Any past or current medical problems or findings on history, physical examination, or laboratory testing, not listed above, that in the opinion of the investigator, may pose additional risk to participation, may interfere with the participant's ability to comply with study requirements, or that may impact the quality or interpretation of study results